Evidence map›Paper›PMID 40960545›Full record

ArticleMikrochimica acta2025

Si@D(AuPt) nanozyme-driven point-of-care testing technology for real-time monitoring of clinical urinary-related indicators.

Guangmin Cheng, Wenlong Bai, Xuanming Zhang, Xuan Xia, Tao Zhang, Dong Feng, Lei Wei, Chongwen Wang, Shu Wang, Shuai Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guangmin Cheng *Department of Nephrology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Wenlong Bai *Hefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230036, China.
Xuanming Zhang *Department of Nephrology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xuan XiaDepartment of Clinical Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510000, Guangdong, China.
Tao ZhangHefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230036, China.
Dong FengHefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230036, China.
Lei WeiHefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230036, China.
Chongwen WangDepartment of Clinical Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510000, Guangdong, China. wangchongwen1987@126.com.
Shu WangHefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230036, China. wangshu@aiofm.ac.cn.
Shuai ZhengHefei Institute of Physical Science, Chinese Academy of Sciences, Hefei, 230036, China. kapposnn@163.com.

Funding

China Postdoctoral Science Foundation 2023M740769National Natural Science Foundation of China 82302638National Natural Science Foundation of China 82372348Science Fund for Distinguished Young Scholars of Guangdong Province 2025B1515020071Scientific and Technological Research on Major Issues in Aviation Medicine of Air Force Medical University 2022ZZXM030
6 · The paper itself

Abstract

To address the challenges of poor system compatibility, low sensitivity, and narrow detection range in traditional colorimetric lateral flow immunochromatographic assay (LFA) for dynamic monitoring of urinary tract infection (UTI) pathogens (biomacromolecules) and antibiotics (small molecules), we propose a colorimetric-enhanced LFA technique based on monodisperse bimetallic composite nanozymes (Si@D(AuPt)), achieving rapid and precise detection of different types of markers in real urinary tract infection samples. The raspberry-like Si@D(AuPt) nanozyme employs a highly stable SiO

Indexed as

Metal NanoparticlesPoint-of-Care TestingUrinary Tract InfectionsAnti-Bacterial AgentsChromatography, AffinityColorimetryGentamicinsGoldHumansLimit of DetectionPseudomonas aeruginosaSilicon DioxideAnti-Bacterial AgentsGentamicinsGoldSilicon DioxideBimetallic composite nanozymesCompetitive modeNanozyme LFAReal-time monitoringSandwich modeUrinary tract infection

Identifiers

PMID40960545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.